Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy-Reference-Cited by-同舟云学术

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Published:2019-12-12 Issue:24 Volume:134 Page:2149-2158
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Gardner Rebecca A.¹²,Ceppi Francesco¹,Rivers Julie¹²,Annesley Colleen¹²,Summers Corinne¹²^ORCID,Taraseviciute Agne¹²,Gust Juliane¹³,Leger Kasey J.¹²^ORCID,Tarlock Katherine¹²,Cooper Todd M.¹²,Finney Olivia C.¹,Brakke Hannah¹,Li Daniel H.⁴,Park Julie R.¹²,Jensen Michael C.¹²

Affiliation:

1. Seattle Children’s Research Institute, Seattle, WA;

2. Department of Pediatrics and

3. Department of Neurology, University of Washington, Seattle, WA; and

4. Clinical Statistics Group, Juno Therapeutics, Inc., Seattle, WA

Abstract

Gardner et al report that early intervention with tocilizumab and steroids at the first signs of mild cytokine release syndrome (CRS) following CD19 chimeric antigen receptor (CAR) T-cell infusion for B-cell acute lymphocytic leukemia reduces the development of life-threatening severe CRS without having a negative impact on antileukemic effect.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/134/24/2149/1547430/bloodbld2019001463.pdf

Reference28 articles.

1. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults;Gardner;Blood,2017

2. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia;Maude;N Engl J Med,2018

3. Chimeric antigen receptor T cells in refractory B-cell lymphomas;Schuster;N Engl J Med,2017

4. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med,2017

5. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy;Hay;Blood,2017

Cited by 218 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An integrated perspective on measuring cytokines to inform CAR-T bioprocessing;Biotechnology Advances;2024-10

2. CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trials;Cancer and Metastasis Reviews;2024-09-09

3. Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention;Frontiers in Immunology;2024-08-26

4. Cytokine release syndrome after CAR T-cell therapy for B-cell acute lymphoblastic leukemia in children and young adolescents: storms make trees take deeper roots;Expert Opinion on Pharmacotherapy;2024-07-23

5. The Kinetics of Inflammation-Related Proteins and Cytokines in Children Undergoing CAR-T Cell Therapy—Are They Biomarkers of Therapy-Related Toxicities?;Biomedicines;2024-07-21